louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05991765: Evaluation of Digit Tip and Split Skin Donor Site Transcriptome
Official title: Evaluation of Digit Tip and Split Skin Donor Site Transcriptome
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Digit Tip Wound
Split Skin Donor Site
Keywords: Digit Tip
Split Skin Donor Site
Transcriptome
Lead sponsor: University Hospital Schleswig-Holstein
Sponsor class: OTHER
First posted: 2023-08-15
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consent-capable patients ≥18 years of age with either Digit Tip Wound or Split Skin Donor Site

Brief summary: Regrowth of amputated fingertips presents a unique regenerative healing process in mammals, with subcutaneous volume regrowth, restoration of the dactylogram, and suppression of scar formation. In addition, wound healing from split-thickness donor sites shows almost scar-free healing. Transcriptome analysis is necessary to better understand the specific healing mechanisms of these two wound entities. Since no data are available to date, this study aims to fill the gap.

Detailed description: Regrowth of amputated fingertips presents a unique regenerative healing process in mammals, with subcutaneous volume regrowth, restoration of the dactylogram, and suppression of scar formation. In addition, wound healing from split-thickness donor sites shows almost scar-free healing. Transcriptome analysis is necessary to better understand the specific healing mechanisms of these two wound entities. Since no data are available to date, this study aims to fill the gap.

Eligibility criteria: Inclusion Criteria:

1. Digit Tip Wound: Wound Exudate from healthy patients: Consent-capable patients ≥18 years of age with clean Digit Tip Wound
2. Split Skin Donor Site Wound: Wound Exudate from healthy patients: Consent-capable patients ≥18 years of age with clean Split Skin Donor Site Wound

Exclusion Criteria:

* Inflammation
* Borderline
* Infectious Disease

Primary outcomes:
measure: Differences in RNA-Expression pattern
timeFrame: 5 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Lübeck
country: Germany
facility: University of Schleswig-Holstein
state: Schleswig-Holstein
Study officials:
References:
Clinical trial NCT05423574: Robotic Trans-Abdominal Retromuscular Umbilical Prosthesis (r-TARUP)
Official title: Feasibility Study of Robotic Trans-Abdominal Retromuscular Umbilical Prosthesis (r-TARUP) for the Treatment of Primary and Incisional Ventral Hernia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ventral Hernia
Keywords: robotic assisted laparoscopy
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2022-06-21
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Major patients undergoing a robotic-assisted laparoscopy procedure for the treatment of ventral hernia repair

Brief summary: Combining the advantage of minimally invasive surgery with laparoscopy to reduce postoperative complications and the placement of a retromuscular prosthesis with closure of the defect in order to reduce the risk of adhesion and restore normal anatomy in the treatment of primary and incisional ventral hernias, is made possible through robotic assistance.

The challenge of this study concerns the evaluation of quality of life, postoperative pain and recurrence at 6 months in the management of primary and incisional ventral hernias by robot-assisted laparoscopic approach.

Detailed description: The robotic-assisted laparoscopic approach for the treatment of primary and secondary ventral hernias is already used in the visceral department of Nancy in France. This technique seems to reduce post operative pain, to improve quality of live and to reduce recurrence. The goal of the study is to evaluate the benefices of this technique. The quality of life, postoperative pain and recurrence will be evaluated at one and six months postoperatively. The recurrence will be evaluated by clinical examination and a computed tomography scan performed at sixth month postoperatively.

Eligibility criteria: Inclusion Criteria:

* major patients undergoing a robotic-assisted laparoscopy procedure for the treatment of ventral hernia repair

Exclusion Criteria:

* patient minor

Primary outcomes:
measure: Recurrence rate at 6 months
timeFrame: 6 months
Secondary outcomes:
measure: Post operative pain
timeFrame: 6 months
Other outcomes:
Locations:
city: Nancy
country: France
facility: Centre Hospitalier Régional Universitaire (CHRU)
Study officials:
References:
Clinical trial NCT06169774: Video Training Supplementation for Patients Discharged on Home Parental Nutrition
Official title: Video Training Supplementation to Reduce the Risk of Central Venous Catheter Infection in Patients Discharged on Home Parental Nutrition
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Intestinal Failure
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2023-12-13
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this clinical trial is to develop an educational video addressing the aseptic techniques to safely handle central catheters for administrating parenteral nutrition at home.

Detailed description: Home parenteral nutrition is an alternative form of providing nutrition to people whose digestive systems either can't absorb or tolerate food eaten by mouth. Parenteral nutrition provides liquid nutrients, including carbohydrates, proteins, fats, vitamins, minerals and electrolytes. In recent years, more emphasis has been placed on delivering parenteral nutrition to patients at home. Studies have shown that patients receiving home parenteral nutrition are at higher risk for bloodstream infections compared to other patients with chronic infusion needs. Catheter-related bloodstream infection is a major cause of mortality and morbidity in patients receiving parenteral nutrition. It is important to maintain safe vascular access to prevent life-threatening complications. This study aims to assess the effectiveness of the video training on the rate of catheter related bloodstream infection over a 12-month period of time.

Eligibility criteria: Inclusion Criteria:

* Taking home parenteral nutrition for the first time
* Willing to self-administer parenteral nutrition
* Age ≥ 18 yrs
* Able to provide informed consent
* Able speak and understand English

Exclusion Criteria:

* Already taking home parenteral nutrition
* not willing to self-administer parenteral nutrition
* Age \< 18 years-old
* Unable to provide informed consent
* Non-English speakers

Primary outcomes:
measure: Quantitative analysis of catheter related bloodstream infection (CRBI) events
timeFrame: baseline-12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
Study officials:
affiliation: University of Chicago
name: Dejan Micic, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00799474: Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination
Official title: Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anus Neoplasms
Lead sponsor: University of North Carolina, Chapel Hill
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2008-11-27
Enrollment: 609
Sex: MALE
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Approximately 600 men (ages 18-59) who have agreed to participate in a periodic panel through the private survey company, Knowledge Networks.

Brief summary: This research focuses on men who have sex with men (MSM) who are at higher risk of anal cancer. The survey will evaluate their beliefs about anal and oral cancer, their knowledge about role of human papillomavirus (HPV) infection in these cancers, and their knowledge of HPV vaccination and anal Pap smears. Approximately 12% of subjects will be HIV-positive.

Detailed description: Little research has examined men's understanding of what causes anal and oral cancers and whether HPV vaccination can play a potential protective role. This research focuses on men who have sex with men (MSM) who are at notably elevated risk of anal cancer, and seeks to characterize their beliefs about anal and oral cancer, knowledge about the etiological role of HPV infection in these cancers, as well as their knowledge of HPV vaccination and anal Pap smears. We will also study heterosexual men.

Eligibility criteria: Inclusion Criteria:

* male
* aged 18-59
* answered question about sexual orientation

Exclusion Criteria:

* none

Primary outcomes:
measure: Willingness to Receive the Human Papillomavirus (HPV) Vaccine
timeFrame: at time of interview
Secondary outcomes:
measure: Awareness of HPV Vaccine
timeFrame: At time of interview
measure: Knowledge of HPV
timeFrame: At time of interview
Other outcomes:
Locations:
Study officials:
affiliation: The University of North Carolina at Chapel Hill, School of Public Health
name: Noel Brewer, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01221974: Use of Essure® Micro-inserts in Women With Hydrosalpinx Prior to In Vitro Fertilization: A Prospective, Multicenter, International Feasibility Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Women Who Suffer From Hydrosalpinx That is Causing Infertility and Whom Want a Safer Way of Treamtent
Keywords: Hydrosalpinx or infertility
Lead sponsor: Reproductive Science Center
Sponsor class: INDUSTRY
Collaborators: name: Shady Grove Fertility
First posted: 2010-10-18
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to gather safety data related to the use of Essure® micro-inserts in women with hydrosalpinx prior to in vitro fertilization and during pregnancy and to collect data with regard to implantation rates, clinical pregnancy rates, and pregnancy outcomes.


Eligibility criteria: Inclusion Criteria:

Women age 21-38 (unless women in ovum donor cycle then age will be included up to 43) who:

Are willing to participate in this clinical study Are able to comprehend and give informed consent for participation in this study Have read, understood and signed an informed consent form Have been unable to achieve pregnancy after trying for 1 year or greater and who have unilateral or bilateral hydrosalpinges as evidenced by laparoscopy or ultrasound or HSG Have a Day #3 serum FSH\<10, and Day #3 Estradiol\<80 Recipient women undergoing a ovum donor cycle the donor must have a Day 3 serum FSH \< 10 and Day 3 Estradiol \< 80 Have an antral follicle count 10 or greater for both ovaries combined, if women using ovum donor (follicle count) will be based on eligible donor Have a desire to receive treatment for their HS Are willing to undergo a hysterosalpingogram (HSG) 3 months after Essure placement to confirm proximal tubal occlusion

Exclusion Criteria:

Active or recent upper or lower pelvic infection Known hypersensitivity to nickel as confirmed by skin test Known allergy to contrast media Pregnancy or suspected pregnancy Delivery or termination of pregnancy less than six weeks prior to Essure micro-insert placements BMI \> 35 Abnormal pap smear (CIN2 or greater abnormality) within the past year Pelvic malignancy Severely retroverted uterus Evidence of intrauterine abnormalities such as submucous fibroids, polyps, intrauterine adhesions or presence of a uterine septum Abnormal Clomid Challenge Test or abnormal lab values on Day #3 serum FSH and Estradiol Antral follicle count less than 10 (both ovaries combined) Poor general or gynecologic health Inability or refusal to provide informed consent

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Ramon
country: United States
facility: Reproductive Science Center
state: California
Study officials:
References:
Clinical trial NCT04734574: Methods of Confirmation of Brain Death
Official title: Use of Different Methods of Confirmation of Brain Death in Brain Death Donors
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Brain Death
Organ Donation
Lead sponsor: Brno University Hospital
Sponsor class: OTHER
First posted: 2021-02-02
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult critically ill patinets with confirmed brain death admitted to university hospital who become brain death organ donor.

Brief summary: The purpose of this study is to describe the use of methods confirming brain death in the real clinical practice of the transplant program in the Czech Republic.

Detailed description: Organ donation is possible in the Czech Republic only after meeting the legislative requirements. These require confirmation of brain death by one of the statutory methods before organ harvesting. The use of these methods in clinical practice has not yet been described.The aim of this retrospective observational study is to describe the use of these methods in the real clinical practice of the transplant program in the Czech Republic, taking into account the legislation of other European countries.

Eligibility criteria: Inclusion Criteria:

* age ≥18 years
* organ donor

Exclusion Criteria:

* age under 18 years

Primary outcomes:
measure: Angiography
timeFrame: within 24 hours after the onset of signs of brain death
measure: Brainstem auditory evoked potentials
timeFrame: within 24 hours after the onset of signs of brain death
measure: Brain scintigraphy
timeFrame: within 24 hours after the onset of signs of brain death
measure: Cerebral computed tomography angiography
timeFrame: within 24 hours after the onset of signs of brain death
measure: Transcranial Doppler ultrasonography
timeFrame: within 24 hours after the onset of signs of brain death
Secondary outcomes:
Other outcomes:
Locations:
city: Brno
country: Czechia
facility: University Hospital Brno
Study officials:
affiliation: University Hospital Brno
name: Roman Gal, M.D., Ph.D.
role: STUDY_CHAIR
References:
Clinical trial NCT04106765: LGI1-antibody Patients Follow-up
Official title: Clinical, EEG and Radiological Initial and Evolutive Characterisation of LGI1-antibody Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Anti-LGI1 Encephalitis
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2019-09-27
Enrollment: 192
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study Population Description : Adult patients presenting an anti-LGI1 autoimmune encephalitis, followed in France and diagnosed by sera or CSF samples at the National Reference Center of autoimmune encephalitis.

Brief summary: Autoimmune encephalitis involve autoantibodies targeting central nervous system, and particularly the synapse or its structure like for LGI1 protein. Anti-LGI1 encephalitis is revealed by an inflammation of the limbic system, with mainly temporal lobe, faciobrachial dystonic or generalized seizures, and cognitive disorders.

This disease is rare and its clinical, EEG and radiological characterisation is not sufficiently established. The investigators will evaluate these three aspects for the anti-LGI1 cohort of patients of the National Reference Center of autoimmune encephalitis.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Diagnosis of anti-LGI1 encephalitis based on sera or CSF samples in the National Reference Center of autoimmune encephalitis from 2011/06 to 2019 july 1st.
* Clinical follow-up in France

Exclusion Criteria:

* Anti-LGI1 antibody associated with another encephalitis antibody
* Foreign follow-up

Primary outcomes:
measure: Evolution of epileptic seizures
timeFrame: 12 MONTHS
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes
Study officials:
affiliation: National Reference Center of autoimmune encephalitis
name: Jerome HONNORAT, pHd
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03733665: HES and NICOR Data Linkage for Cardiac Failure Population Analysis
Official title: HES and NICOR Data Linkage for Cardiac Failure Population Analysis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Heart Failure
Registries
Patient Readmission
Keywords: Hospital Episode Statistics
HES
National Institute for Cardiovascular Outcomes Research
NICOR
National Heart Failure Audit
Lead sponsor: King's College London
Sponsor class: OTHER
First posted: 2018-11-07
Enrollment: 80000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Acute decompensated heart failure (ADHF) is a sudden worsening of the signs and symptoms of heart failure, which typically includes difficulty breathing (dyspnoea) and leg oedema. ADHF is a common and potentially serious cause of acute respiratory distress. Treatment of ADHF consists of reducing the excess fluid retention with diuretics along with improving heart function with pharmacological treatment. Although pharmacological treatments exist for heart failure patients with reduced ejection fraction (ACE inhibitors, beta-blockers), a substantial fraction of patients exhibit preserved ejection fraction where treatment consists solely of management of comorbidities and symptoms.

Brief summary: This study is a population-based, patient-level analysis of heart failure in England over a 5-year period using a dataset created by linking HES and NICOR databases. Our analyses will look into the re-occurrence of hospitalisation after the initial diagnosis of heart failure, the influence of population factors on risk of re-hospitalisation, and the resultant cost implications in an NHS environment.

Detailed description: Data from the National Heart Failure Audit (NICOR) and Hospital Episodes Statistics (NHS Digital) will be linked, by NHS Digital, using fields that are recorded in both databases (for example, NHS number). We will receive de-anonymised data that has been pseudo-anonymised, allowing for patient-level analyses but without identifying individual patients.

Eligibility criteria: Inclusion Criteria:

* patients \>17 years old
* individual patient data appears on both HES and NICOR databases
* 4-character primary diagnosis codes I50.0-I50.9

Exclusion Criteria:

* patient requests withdrawal from analyses

Primary outcomes:
measure: Readmission
timeFrame: 2012-2017
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: King's College London
Study officials:
affiliation: King's College London
name: Anastasia Chalkidou
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05790265: Assessing Innovative Wireless and Wearable Sensors for Continuous Blood Pressure Measurement in Obese Pregnant Women
Official title: Assessing Innovative Wireless and Wearable Sensors for Continuous Blood Pressure Measurement in Obese and Super-obese Pregnant Women
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Blood Pressure
Lead sponsor: Sibel Health Inc.
Sponsor class: INDUSTRY
Collaborators: name: University of North Carolina
First posted: 2023-03-30
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study is a prospective study targeting at least 20 obese and super-obese patients admitted to Labor \& Delivery (L\&D) for delivery at UNC Medical Center. Patients with clinical indicated radial A-lines either planned or already in-situ will be offered participation. The study will evaluate the accuracy of noninvasive blood pressure measurements with the ANNE One system to blood pressure readings with the radial A-line.


Eligibility criteria: Inclusion Criteria:

* Age \>= 18 years old
* Ability and willingness to provide written informed consent
* Admitted for delivery at UNC Medical Center
* BMI of \>= 40 kg/m2
* Clinically indicated radial A-lines either planned or already in-situ prior to delivery

Exclusion Criteria:

* Skin sensitivity or allergy that precludes placement of ANNE One
* Any condition (social or medical) which, in the opinion of the study staff would make any study participation unsafe or complicate data interpretation
* Expected delivery within \<= 1 hour of arrival to L\&D

Primary outcomes:
measure: Mean absolute error (MAE) and standard deviation of blood pressure measurements with ANNE One compared to arterial line
timeFrame: 8 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: